摘要
目的探讨沙美特罗替卡松联合孟鲁司特钠治疗中重度支气管哮喘急性发作的临床效果。方法选取2019年1月—2020年12月济南市长清区人民医院收治的135例中重度支气管哮喘急性发作患者作为研究对象,按照随机数字表法分为对照组(68例)与治疗组(67例)。对照组采用沙美特罗替卡松雾化吸入治疗,治疗组在对照组治疗的基础上给予孟鲁司特纳治疗。比较两组的临床疗效、治疗前后的肺功能指标、不良反应总发生率。结果治疗组的临床疗效优于对照组,差异有统计学意义(P<0.05)。治疗前两组的第1秒用力呼气容积(FEV_(1))和最大呼气流量(PEF)水平比较,差异无统计学意义(P>0.05)。治疗后两组的FEV_(1)与PEF水平高于治疗前,且治疗组的FEV_(1)与PEF水平高于对照组,差异有统计学意义(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论沙美特罗替卡松联合孟鲁司特钠治疗中重度支气管哮喘急性发作的临床效果显著,患者肺功能明显改善,且不增加不良反应,值得临床推广应用。
Objective To investigate the clinical effect of Salmeterol and Fluticasone combined with Montelukast Sodium in the treatment of acute attack of moderate to severe bronchial asthma.Methods A total of 135 patients with acute attack of moderate to severe bronchial asthma in Changqing District People′s Hospital of Ji′nan City from January 2019 to December 2020 were selected as the research objects.According to the random number table method,the patients were divided into the control group(68 cases)and the treatment group(67 cases).The patients of the control group were given Salmeterol and Fluticasone aerosol inhalation,while the patients of the treatment group were given Montelukast Sodium on the basis of the control group.The clinical efficacy,pulmonary function indexes before and after treatment and the incidence of adverse reactions were compared between the two groups.Results The clinical efficacy of the treatment group was better than that of the control group,the difference was statistically significant(P<0.05).There was no statistical significance in the level of forced expiratory volume in one second(FEV_(1))and peak expiratory flow(PEF)in the first second before treatment(P>0.05).The levels of FEV_(1) and PEF in the patients of the two groups after treatment were higher than those before treatment,the differences were statistically significant(P<0.05).The levels of FEV_(1) and PEF in the treatment group were higher than those in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the patients in the two groups(P>0.05).Conclusion The clinical effect of Salmeterol Fluticasone combined with Montelukast Sodium in the treatment of acute attack of moderate to severe bronchial asthma is significant,which can significantly improve the lung function of patients,and does not increase adverse reactions,it is worthy of clinical promotion and application.
作者
宋庆军
SONG Qing-jun(Department of Respiratory,Changqing District People′s Hospital in Ji′nan City,Shandong Province,Ji′nan 250300,China)
出处
《中国当代医药》
CAS
2021年第25期63-65,共3页
China Modern Medicine
关键词
中重度支气管哮喘急性发作
沙美特罗替卡松
孟鲁司特钠
临床效果
Acute attack of moderate to severe bronchial asthma
Salmeterol and Fluticasone
Montelukast Sodium
Clinical effect
